Topic

02

Bredin Prat advises Juvisé Pharmaceuticals in connection with Bpifrance and Pemberton acquiring a stake in its capital

Published on — Press releases

Bredin Prat is advising Juvisé Pharmaceuticals and its shareholder in connection with Bpifrance and Pemberton acquiring a stake in its capital in relation to the purchase by Juvisé Pharmaceuticals of the global marketing rights for PONVORY® (excluding the United States and Canada), a multiple sclerosis drug, from Actelion Pharmaceuticals Ltd, a Johnson & Johnson company.

The acquisition of PONVORY® is funded via a combination of a share capital increase, additional debt provided by Pemberton Asset Management (a leading European private credit manager), and a shareholder loan.

The French state-owned investment entity Bpifrance and Pemberton Asset Management have acquired a minority stake in Juvisé Pharmaceuticals.

The Bredin Prat team advising Juvisé Pharmaceuticals includes:

  • Corporate: Olivier Assant (partner), Jérôme Vincent and Thomas Delacour
  • Tax law: Anne Robert and Jean-Baptiste Frantz (partners), Paul Cauchin